Roche to acquire Carmot Therapeutics and with it, incretins with best-in-class potential to treat obesity.
Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc., a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs
The acquisition gives Roche access to a differentiated portfolio of incretins including: i.CT 388, the lead asset is a Phase-II ready, dual GLP-1/GIP receptor agonist for the treatment of obesity in patients with and without type 2 diabetes. Injected subcutaneously once a week, it has potential as a standalone and combination therapy to improve weight loss and to be expanded to other indications. ii.CT 996, a once-daily oral, small molecule GLP-1 receptor agonist currently in Phase-1 intended to treat obesity in patients with and without type 2 diabetes. iii. CT 868, a Phase-II, once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist intended for the treatment of type 1 diabetes patients with overweight or obesity. The existing clinical data for Carmot’s assets, especially the lead asset CT 388, suggests a best-in-class potential to achieve and maintain weight loss with differentiated efficacy. Moreover, the assets provide an opportunity for combinations with existing Roche pipeline assets including ones focused on other benefits, such as preserving muscle mass. Incretins are gut hormones that are secreted after food intake and play a role in modulating blood glucose by stimulating insulin secretion and suppressing appetite. The incretin-based portfolio could also be expanded to other indications where incretins play a role including cardiovascular, retinal and neurodegenerative disease.
Related news and insights
Invitae, a leading medical genetics company, announced that it is building on previous actions to manage costs and improve its business structure by filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey
LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced that the Company’s Board of Directors had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares, each representing the right to receive one ordinary share, from the Nasdaq Global Market and deregistration under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and workforce reductions
Gilead Sciences, Inc.and CymaBay Therapeutics, Inc. announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion